Quick Answer
Dianthus Therapeutics, Inc. /DE/ reported Stockholders Equity of $493.40 million for the year ending 2025.
- Dianthus Therapeutics, Inc. /DE/ showed an increase of +40.0% in Stockholders Equity from 2024 to 2025.
- This data is from Dianthus Therapeutics, Inc. /DE/'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$51.85 million | Q2 2018: $172.22 million | Q3 2018: $159.78 million | Q1 2019: $134.00 million | Q2 2019: $179.56 million | Q3 2019: $161.53 million | Q1 2020: $125.40 million | Q2 2020: $173.91 million | Q3 2020: $158.57 million | Q1 2021: $129.06 million | Q2 2021: $202.89 million | Q3 2021: $189.69 million | Q1 2022: -$22.07 million | Q2 2022: -$27.48 million | Q3 2022: -$34.75 million | Q1 2023: -$50.82 million | Q2 2023: -$61.46 million | Q3 2023: $178.38 million | Q1 2024: $372.69 million | Q2 2024: $358.22 million | Q3 2024: $337.90 million | Q1 2025: $328.61 million | Q2 2025: $303.08 million | Q3 2025: $546.45 million.
- Over the full 11 years of available data (2015 to 2025), Dianthus Therapeutics, Inc. /DE/'s Stockholders Equity has grown by 170,827.0%.
- Historical annual values: Fiscal year 2025: $493.40 million | Fiscal year 2024: $352.48 million | Fiscal year 2023: $168.87 million | Fiscal year 2022: -$44.37 million | Fiscal year 2021: -$17.25 million | Fiscal year 2020: $143.91 million | Fiscal year 2019: $141.19 million | Fiscal year 2018: $145.65 million | Fiscal year 2017: -$42.12 million | Fiscal year 2016: -$8.87 million | Fiscal year 2015: -$289.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: